| Document |
Document Title |
|
JP2014501716A |
Antibacterial compounds of Formula I are provided: as well as stereoisomers and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administrat...
|
|
JP5397461B2 |
Provided are: a compound represented by formula (I): (wherein ring A and ring D each represent a cyclic group which may have a substituent(s); E and G each represent a bond or a spacer having 1 to 8 atoms in its main chain; L represents ...
|
|
JP5395668B2 |
Cyclopentyl (2 S )-cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3 yl}methyl)amino]acetate inhibits HDAC activity.
|
|
JP2013241423A |
To provide a covalently linked complex which is hydrolyzed by carboxylesterase within the cell to perform enzyme or receptor modification which is enhanced or more extended relative to an inhibitor which is accumulated in a target cell a...
|
|
JP5341973B2 |
Asymmetric fluorene compounds are formed by reacting an amide starting material; reacting the resultant ketone with a further equivalent of a different organometallic reagent; and a ring closing elimination reaction. Formation of a compo...
|
|
JP5330324B2 |
The invention provides novel PGF analogs. In particular, the present invention relates to compounds having a structure according to the following formula: wherein R1, R2, R3, R4, X, and Z are as defined. This invention also includes opti...
|
|
JP5322309B2 |
The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and ...
|
|
JP5323496B2 |
Stable complexes are described, formed by mono- and di-functional compounds bound to nanoparticles composed of various types of transition metal oxides and of metals useful in the production processes of different types of new materials ...
|
|
JP5304981B2 |
There is provided a novel process intermediate represented by the general formula (1) or (2): (where, X represents halogen atom, cyano group or the like, Y represents halogen atom, cyano group or the like, R 1 represents C 1 -C 6 haloalk...
|
|
JP5290065B2 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell pr...
|
|
JP5277171B2 |
The present invention discloses novel naphthalenyloxypropenyl derivatives useful for inhibiting the enzyme activity of histone deacctylase, leading effective suppression of cancer cell proliferation.
|
|
JP5277213B2 |
Antibacterial compounds of formula (I) are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; treating bacterial infections by the a...
|
|
JP2013129665A |
To provide a compound useful for treatment of various metabolic disruptions (for instance, insulin resistant syndrome, diabetes, hyperlipemia, fatty liver disease, cachexia, obesity, atherosclerosis, and arteriosclerosis).This compound i...
|
|
JP2013112666A |
To provide a method for producing an aromatic hydroxamic acid derivative by a simple means and with a high yield.In a method for producing an aromatic hydroxamic acid derivative represented by general formula (II) by making an aromatic o...
|
|
JP2013100327A |
To provide a compound serving as a histone deacetylase inhibitor particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis.The compound represented by formula (I...
|
|
JP5199087B2 |
Novel PDF inhibitors and novel methods for their use are provided.
|
|
JP5193862B2 |
The present invention relates to compounds of formula (I), where R1 and R2, which may be identical or different, are selected from the group comprising H, CnH2n-1, a linear or branched alkyl group having 1 to 6 carbons, or together form ...
|
|
JP5190366B2 |
Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-
dioxo-1 (2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of ...
|
|
JPWO2011055843A1 |
The present invention provides a substance (hereinafter referred to as a retinoid compound) that acts on a retinoic acid receptor, which is a nuclear receptor. In the formula, R1And R2Are independent NH2, Alkyl group and alkoxy group sel...
|
|
JP5166872B2 |
The present invention provides a compound represented by the following general formula (I): or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceu...
|
|
JP5160091B2 |
Use of osteopontin for reducing plaque bacterial growth on tooth enamel and dental formulations containing osteopontin.
|
|
JP2013018783A |
To provide bifunctional histone deacetylase inhibitors.In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel bifunctional, trifunctional, or m...
|
|
JP5124461B2 |
Novel dioxazine- and oxdiazine-substituted arylamides of the formula (I) in which A1, A2, R1, R2, R3, R4 and R5 are as defined in the description, a plurality of processes for preparing these compounds and their use for controlling pests...
|
|
JP5107579B2 |
Zn2+-chelating motif-tethered fatty acids as histone deacetylase (HDAC) inhibitors. Compounds performed well in in vitro and in vivo tests.
|
|
JP5086635B2 |
Antibacterial compounds of formula (I) are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; treating bacterial infections by the a...
|
|
JP5080462B2 |
Biphenyl and phenyl-naphthyl compounds bearing a hydroxamic group, which are endowed with antitumor, and anti-angiogenic activity These compounds are therefore particularly useful for the treatment of drug-resistant tumors.
|
|
JP2012527435A |
A compound of formula (I) wherein R1 to R15, P1, P2, A, B and Q are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as matriptase inhibitors a...
|
|
JP2012211195A |
To reduce plaque bacterial growth on tooth enamel.The invention relates to the use of osteopontin for reducing plaque bacterial growth on tooth enamel and dental formulations containing osteopontin.
|
|
JP5063860B2 |
Diamidine derivatives of formula (I) and their salts are new. Amidine derivatives of formula (I) and their salts are new. [Image] X : a group of formula (ii) or R 4; Z : -(CH 2) m-; m : 8 - 21; n : 0 or 1; Y : R 3 or a group of formula (...
|
|
JP5009480B2 |
The present invention relates to 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives and their use in therapy, in particular their use as nitric oxide synthase inhibitors.
|
|
JP2012153902A |
To provide an improved curative capable of being more easily dispersed in a perfluoroelastomer, particularly a cyano curable perfluoroelastomer and more rapidly curing the perfluoroelastomer, particularly cyano curable perfluoro elastome...
|
|
JP4993374B2 |
The present invention is directed to prodrugs of hydroxamic acid based histone deacetylase (HDAC) inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The prodrugs are acylated derivatives having increased aqueous solubility and cel...
|
|
JP2012140438A |
To provide 7-substituted tetracycline compounds used for treatment of numerous tetracycline compound-responsive states such as bacterial infections and neoplasms, as well as for other known applications for minocycline and tetracycline c...
|
|
JP4975201B2 |
Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
|
|
JP4946861B2 |
Compounds having the formula (I): wherein R1 is hydrogen, lower alkyl, lower alkenyl, lower or higher alkynyl, cyclo(lower)alkyl, cyclo(higher)alkyl, cyclo(lower)alkyl(lower)alkyl, cyclo(higher)alkyl(lower)alkyl, cyclo(lower)alkenyl(lowe...
|
|
JP4939941B2 |
|
|
JP4937479B2 |
N-(2-aryl-propionyl)-amides of formula (I) are described. The process for their preparation and pharmaceutical preparations thereof are also described. The amides of the invention are useful in the prevention and treatment of tissue dama...
|
|
JP4939216B2 |
The invention provides novel compounds according to formula I relates to compounds with the general formula I said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases or cancer.
|
|
JP2012092121A |
To provide an aqueous prodrug of a histone deacetylase (HDAC) inhibitor of a hydroxamic acid base.Suberoylanilide hydroxamic acid derivative is expressed by formula (4). In formula (4), Ra is CORb, and Rb is hydrogen, un-substituted or s...
|
|
JP4931419B2 |
A compound of the present invention, or a pharmaceutically acceptable salt thereof is indicated by formula (1) below: wherein, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , Q, R 8 , and R 9 have the same meanings as R 1 , R 2 , R 3 , R 4 , R 5 , R...
|
|
JP4929717B2 |
The present invention provides a process for preparing an N,N'-dialkoxy-N,N'-dialkyl oxamide represented by the formula (3) : wherein R 2 and R 3 may be the same or different from each other, and each represent an alkyl group having 1 to...
|
|
JP2012509929A |
The present invention relates to crystalline forms of the active pharmaceutical ingredient vorinostat, processes for their preparation and their use in pharmaceutical compositions. Formula (I).
|
|
JP2012509930A |
The present invention relates to crystalline forms of the active pharmaceutical ingredient vorinostat, processes for their preparation and their use in pharmaceutical compositions.
|
|
JP4921167B2 |
A compound of formula (I), or an enantiomer or diastereoisomer thereof, or a salt, hydrate or solvate thereof: for the treatment or prophylaxis of arthritis in mammals.
|
|
JP4922521B2 |
From compounds of formula II wherein R1 and R2 are independently of one another H, C1-C6alkyl, C1-C6halogenalkyl, C1-C6alkoxy, C1-C6alkoxy-C1-C6alkyl, or C1-C6alkoxy-C1-C6alkyloxy, R3 is C1-C6alkyl, R4 is C1-C6alkyl, and R5 is C1-C6alkyl...
|
|
JP4918456B2 |
This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bo...
|
|
JP4903155B2 |
2-cyclopenten-1-one oxime derivatives represented by Formula (I), or pharmaceutically acceptable salts thereof inhibit the production of TNF-α or PDE4, and therefore show therapeutic effect in inflammatory or immunological disorders med...
|
|
JP4875978B2 |
A compound represented by the formula (1): wherein each symbol is as defined in the specification, and a salt thereof and a prodrug thereof unexpectedly have superior GPR40 receptor agonist activity, superior in the properties as a pharm...
|
|
JP2012500222A |
The present disclosure provides compounds having the general structure A or pharmaceutically acceptable salts thereof: R—X (A) wherein R is an alkyl or aryl moiety comprising heterocyclic structures; and X is a metal-chelatin grou...
|
|
JP4844961B2 |
To provide compounds which have high angiogenesis inhibiting activity, and are useful as agents for effective treatment and prevention of diseases involving pathologic angiogenesis, for example, cancer and cancer metastasis, methods for ...
|
